<?xml version="1.0" encoding="utf-8"?>
<!DOCTYPE trials [
<!ELEMENT trials (trial+)>

<!ELEMENT trial (main,contacts,countries,criteria,health_condition_code,health_condition_keyword,intervention_code,
          intervention_keyword,primary_outcome,secondary_outcome,secondary_sponsor,secondary_ids,source_support,ethics_reviews)>

<!ELEMENT main (trial_id,utrn?,reg_name,date_registration,primary_sponsor,public_title,acronym?,scientific_title,scientific_acronym?,
          date_enrolment,type_enrolment,target_size,recruitment_status,url?,study_type,study_design,phase,hc_freetext?,i_freetext?,results_actual_enrolment,results_date_completed,results_url_link,results_summary,           results_date_posted,results_date_first_publication,results_baseline_char,results_participant_flow,results_adverse_events,results_outcome_measures,results_url_protocol,results_IPD_plan, results_IPD_description)>
<!ELEMENT trial_id (#PCDATA)>
<!ELEMENT utrn (#PCDATA)>
<!ELEMENT reg_name (#PCDATA)>
<!ELEMENT date_registration (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT primary_sponsor (#PCDATA)>
<!ELEMENT public_title (#PCDATA)>
<!ELEMENT acronym (#PCDATA)>
<!ELEMENT scientific_title (#PCDATA)>
<!ELEMENT scientific_acronym (#PCDATA)>
<!ELEMENT date_enrolment (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT type_enrolment (#PCDATA)>
<!ELEMENT target_size (#PCDATA)>
<!ELEMENT recruitment_status (#PCDATA)><!-- Pending,Recruiting,Suspended,Complete,Other -->
<!ELEMENT url (#PCDATA)>
<!ELEMENT study_type (#PCDATA)><!-- interventional,observational -->
<!ELEMENT study_design (#PCDATA)>
<!ELEMENT phase (#PCDATA)>
<!ELEMENT hc_freetext (#PCDATA)>
<!ELEMENT i_freetext (#PCDATA)>
<!ELEMENT results_actual_enrolment (#PCDATA)>
<!ELEMENT results_date_completed (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_url_link (#PCDATA)>
<!ELEMENT results_summary (#PCDATA)>
<!ELEMENT results_date_posted (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_date_first_publication (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_baseline_char (#PCDATA)>
<!ELEMENT results_participant_flow (#PCDATA)>
<!ELEMENT results_adverse_events (#PCDATA)>
<!ELEMENT results_outcome_measures (#PCDATA)>
<!ELEMENT results_url_protocol (#PCDATA)>
<!ELEMENT results_IPD_plan (#PCDATA)>
<!ELEMENT results_IPD_description (#PCDATA)>


<!ELEMENT contacts (contact+)>
<!ELEMENT contact (type,firstname,middlename,lastname,address,city,country1,zip,telephone,email,affiliation)>
<!ELEMENT type (#PCDATA)><!-- Public,Scientific -->
<!ELEMENT firstname (#PCDATA)>
<!ELEMENT middlename (#PCDATA)>
<!ELEMENT lastname (#PCDATA)>
<!ELEMENT address (#PCDATA)>
<!ELEMENT city (#PCDATA)>
<!ELEMENT country1 (#PCDATA)>
<!ELEMENT zip (#PCDATA)>
<!ELEMENT telephone (#PCDATA)>
<!ELEMENT email (#PCDATA)>
<!ELEMENT affiliation (#PCDATA)>

<!ELEMENT countries (country2+)>
<!ELEMENT country2 (#PCDATA)>

<!ELEMENT criteria (inclusion_criteria,agemin,agemax,gender,exclusion_criteria)>
<!ELEMENT inclusion_criteria (#PCDATA)>
<!ELEMENT agemin (#PCDATA)>
<!ELEMENT agemax (#PCDATA)>
<!ELEMENT gender (#PCDATA)>
<!ELEMENT exclusion_criteria (#PCDATA)>

<!ELEMENT health_condition_code (hc_code+)>
<!ELEMENT hc_code (#PCDATA)>

<!ELEMENT health_condition_keyword (hc_keyword+)>
<!ELEMENT hc_keyword (#PCDATA)>

<!ELEMENT intervention_code (i_code+)>
<!ELEMENT i_code (#PCDATA)>

<!ELEMENT intervention_keyword (i_keyword+)>
<!ELEMENT i_keyword (#PCDATA)>

<!ELEMENT primary_outcome (prim_outcome+)>
<!ELEMENT prim_outcome (#PCDATA)>

<!ELEMENT secondary_outcome (sec_outcome+)>
<!ELEMENT sec_outcome (#PCDATA)>

<!ELEMENT secondary_sponsor (sponsor_name+)>
<!ELEMENT sponsor_name (#PCDATA)>

<!ELEMENT secondary_ids (secondary_id+)>
<!ELEMENT secondary_id (sec_id,issuing_authority)>
<!ELEMENT sec_id (#PCDATA)>
<!ELEMENT issuing_authority (#PCDATA)>

<!ELEMENT source_support (source_name+)>
<!ELEMENT source_name (#PCDATA)>

<!ELEMENT ethics_reviews (ethics_review+)>
<!ELEMENT ethics_review (status,approval_date,contact_name,contact_address,contact_phone,contact_email)>
<!ELEMENT status (#PCDATA)><!-- Not approved,Approved,NA -->
<!ELEMENT approval_date (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT contact_name (#PCDATA)>
<!ELEMENT contact_address (#PCDATA)>
<!ELEMENT contact_phone (#PCDATA)>
<!ELEMENT contact_email (#PCDATA)>
]>
<trials>
  <trial>
    <main>
      <trial_id>IRCT20191201045566N1</trial_id>
      <utrn></utrn>
      <reg_name>IRCT</reg_name>
      <date_registration>2020-09-06</date_registration>
      <primary_sponsor>Ahvaz University of Medical Sciences</primary_sponsor>
      <public_title>Comparison of midazolam – propofol versus midazolam – ketamin in sedative endoscopy in out patients</public_title>
      <acronym></acronym>
      <scientific_title>Comparison of midazolam – propofol versus midazolam – ketamin in sedative endoscopy in out patients since April until the end of November 2019 at the Ahvaz Imam Khomeini Hospital</scientific_title>
      <scientific_acronym></scientific_acronym>
      <date_enrolment>2019-09-30</date_enrolment>
      <type_enrolment>anticipated</type_enrolment>
      <target_size>78</target_size>
      <recruitment_status>Complete</recruitment_status>
      <url>https://irct.ir/trial/43923</url>
      <study_type>interventional</study_type>
      <study_design>Randomization: Randomized, Blinding: Double blinded, Placebo: Not used, Assignment: Parallel, Purpose: Treatment, Randomization description: Simple Randomization Method
Individual Randomization Unit
Randomization Tool: Statistical software, Blinding description: This study is a double blind study after the patient is fully aware of the research and the researcher and patient are not aware of the type of prescription drugs.</study_design>
      <phase>2-3</phase>
      <hc_freetext>Endoscopy.</hc_freetext>
      <i_freetext>Intervention 1: Intervention group: Both groups were given fentanyl at a dose of 0.5 micrograms per kilogram. In group A, midazolam was administered intravenously at a rate of 0.5 micrograms per kilogram for each patient of standard weight, followed by bolus injection of 0.7 milligrams per kilogram of propofol. If necessary, an infusion of propofol at one-third of the initial dose was used. Intervention 2: Intervention group: Fentanyl was administered at a dose of 0.5 micrograms per kilogram. In group B, ketamine at a dose of 0.5 milligrams per kilogram was injected as a bolus and midazolam at a dose of 0.5 micrograms per kilogram, if necessary. Propofol infusion was used at a rate of one third of the initial dose.</i_freetext>
      <results_actual_enrolment></results_actual_enrolment>
      <results_date_completed></results_date_completed>
      <results_url_link></results_url_link>
      <results_summary></results_summary>
      <results_date_posted></results_date_posted>
      <results_date_first_publication></results_date_first_publication>
      <results_baseline_char></results_baseline_char>
      <results_participant_flow></results_participant_flow>
      <results_adverse_events></results_adverse_events>
      <results_outcome_measures></results_outcome_measures>
      <results_url_protocol></results_url_protocol>
      <results_IPD_plan>Yes - There is a plan to make this available</results_IPD_plan>
      <results_IPD_description>What will be shared:
All potential data can be shared after unidentified individuals

When:
Start of access period 6 months after printing the results

To whom:
It will be available only to researchers working in academic and scientific institutions

Conditions:
For the purpose of scientific research in the field of anesthesia and in compliance with medical ethics

Where to obtain:
Ahvaz - University City - Ahvaz Jundishapur University of Medical Sciences - Central Library Building - First Floor - PO Box: 158 Postal Code: 15794-61357 Phone 3311-061 E-mail: info@ajums.ac.ir

How to obtain:
Request by e-mail from the Central Library of Jundishapur University of Medical Sciences and then check the eligibility to provide data to individuals and then the availability of data

Comments:
</results_IPD_description>
    </main>
    <contacts>
      <contact>
        <type>public</type>
        <firstname>Dr Reza Baqbanian</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>Imam Khomeini Medical Center of Ahvaz, Azadegan St.</address>
        <city>Ahvaz</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip>6193673166</zip>
        <telephone>+98 61 3222 0168</telephone>
        <email>baghbanian-r@ajums.ac.ir</email>
        <affiliation>Ahvaz University of Medical Sciences</affiliation>
      </contact>
      <contact>
        <type>scientific</type>
        <firstname>Dr Reza Baqbanian</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>Imam Khomeini Medical Center of Ahvaz, Azadegan St.</address>
        <city>Ahvaz</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip>6193643166</zip>
        <telephone>+98 61 3222 0168</telephone>
        <email>baghbanian-r@ajums.ac.ir</email>
        <affiliation>Ahvaz University of Medical Sciences</affiliation>
      </contact>
    </contacts>
    <countries>
      <country2>Iran (Islamic Republic of)</country2>
    </countries>
    <criteria>
      <inclusion_criteria>All endoscopic patients
Age 20 to 60 years
Weight 55 to 85 kg
Being in ASA class one or two</inclusion_criteria>
      <agemin>20 years</agemin>
      <agemax>60 years</agemax>
      <gender>Both</gender>
      <exclusion_criteria>Blood pressure history
Diabetes
Respiratory failure
Liver problem
Kidney problem
Addiction
Heart disease
Drug allergy</exclusion_criteria>
    </criteria>
    <health_condition_code>
      <hc_code></hc_code>
    </health_condition_code>
    <health_condition_keyword>
      <hc_keyword></hc_keyword>
    </health_condition_keyword>
    <intervention_code>
      <i_code>Other</i_code>
      <i_code>Other</i_code>
    </intervention_code>
    <intervention_keyword>
      <i_keyword>Intervention group: Both groups were given fentanyl at a dose of 0.5 micrograms per kilogram. In group A, midazolam was administered intravenously at a rate of 0.5 micrograms per kilogram for each patient of standard weight, followed by bolus injection of 0.7 milligrams per kilogram of propofol. If necessary, an infusion of propofol at one-third of the initial dose was used</i_keyword>
      <i_keyword>Intervention group: Fentanyl was administered at a dose of 0.5 micrograms per kilogram. In group B, ketamine at a dose of 0.5 milligrams per kilogram was injected as a bolus and midazolam at a dose of 0.5 micrograms per kilogram, if necessary. Propofol infusion was used at a rate of one third of the initial dose.</i_keyword>
    </intervention_keyword>
    <primary_outcome>
      <prim_outcome>Sedation. Timepoint: From the moment of injection and during injection and after waking up. Method of measurement: Based on the Ramsey variable.</prim_outcome>
      <prim_outcome>Comparison of nausea and vomiting in two groups of midazolam - propofol with midazolam - ketamine in patients undergoing outpatient endoscopy. Timepoint: From the end of the procedure to the time of leaving the recovery. Method of measurement: Visual analoge scale.</prim_outcome>
      <prim_outcome>Comparison of postoperative pain in patients in two groups of midazolam-propofol with midazolam-ketamine in patients undergoing outpatient endoscopy. Timepoint: At the beginning of the procedure, the end of the procedure and one hour after the end of the procedure. Method of measurement: Ambesh score.</prim_outcome>
      <prim_outcome>Comparison of recovery time in patients between the two groups of midazolam-propofol with midazolam-ketamine in patients undergoing outpatient endoscopy. Timepoint: From the time the procedure was completed to the patient's alertness and appropriate response to questions, recovery time was considered (every 30 seconds, recovery was assessed). Method of measurement: Less than 5 minutes fast, between 5-10 minutes medium and more than 10 minutes slow recovery.</prim_outcome>
      <prim_outcome>Comparison of hemodynamic changes in the two groups of midazolam-propofol with midazolam-ketamine in patients undergoing outpatient endoscopy. Timepoint: Vital signs (including heart rate, systolic and diastolic blood pressure, and oxygen saturation) before, and during, induction. Method of measurement: Heart rate per minute and systolic and diastolic blood pressure based on millimeters of mercury and arterial blood oxygen saturation.</prim_outcome>
      <prim_outcome>Age, sex and weight in patients in the two groups of midazolam - propofol with midazolam - ketamine in patients undergoing outpatient endoscopy. Timepoint: On arrival. Method of measurement: Age based on number of years of life and weight based on kg and sex based on phenotype.</prim_outcome>
    </primary_outcome>
    <secondary_outcome>
      <sec_outcome></sec_outcome>
    </secondary_outcome>
    <secondary_sponsor>
      <sponsor_name></sponsor_name>
    </secondary_sponsor>
    <secondary_ids>
      <secondary_id>
        <sec_id></sec_id>
        <issuing_authority></issuing_authority>
      </secondary_id>
    </secondary_ids>
    <source_support>
      <source_name>Ahvaz University of Medical Sciences</source_name>
    </source_support>
    <ethics_reviews>
      <ethics_review>
        <status>Approved</status>
        <approval_date>2019-09-28</approval_date>
        <contact_name>Ethics committee of Ahvaz Jundishapur University of Medical Sciences</contact_name>
        <contact_address>Ahvaz University City - Deputy of Research and Technology - Information Office Ahvaz Khouzestan Iran (Islamic Republic of)</contact_address>
        <contact_phone></contact_phone>
        <contact_email></contact_email>
      </ethics_review>
    </ethics_reviews>
  </trial>
</trials>
